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Background/objective: Weurgently need novel treatments formultidrug-resistant tuberculosis
(MDR-TB). Autologousmesenchymal stromal cell (MSC) infusion is one such possibility due to
its potential to repair damaged lung tissue and boost immune responses. We aimed to assess
the safety and effectiveness ofMSC to improve treatment outcomes amongMDR-TB patients.
Methods: We analyzed treatment outcomes for 108 Belarusian MDR-TB patients receiving
chemotherapy. Thirty-six patients (cases) also had MSCs collected, extracted, cultured, and
reinfused (average time from chemotherapy start to infusion was 49 days) in optimal dose;
another 36 patients (without MSC treatment) were ‘‘study controls”. We identified another
control group: 36 patients from the Belarusian national surveillance database (surveillance
controls) 1:1 matched to cases.
Results: Successful outcomeswere observed in 81% of cases, 42% of surveillance controls, and
39% of study controls. After adjusting for age, odds of a successful outcome were 6.5 (95%
confidence interval, 1.2–36.2, p = 0.032) times greater for cases than surveillance controls.
Adjusting for other potential confounders increased the effect estimate while maintaining
statistical significance. Caseswere less likely (p = 0.01) to be culture negative at 2 months than
surveillance controls, indicating a poorer initial prognosis in cases before (or shortly after)
infusion. Radiological improvement was more likely in cases than in study controls.
Conclusion: MSC treatment could vastly improve treatment outcomes for MDR-TB patients.
Our findings could revolutionize therapy options and have strong implications for future
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